# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Mumtaz Mahal (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-RE006-SYN
- Date: 2026-01-06
- Fictional facility: St. Posthumous Health Center
- Fictional author: Farzana Qureshi-Lindholm, MD
- Calendar frame: modern shifted

## What we are working on

- Pregnant again soon after her last baby; tired and breathless on stairs, and unsure how far along she is **S**
- She has lost six children and wants to do everything possible for this baby and to be well enough for the children she has **S**
- Her family may travel again during the pregnancy and she wants to know when and how she can travel safely **S**

## Your goals

- Hemoglobin at least 11 g/dL with replete iron stores before delivery. Target: 2026-06-02. Recorded outcome: Hemoglobin 11.8 g/dL and ferritin 110 ng/mL after two doses of intravenous iron. **S**
- An informed choice about aneuploidy screening by 14 weeks. Target: 2026-02-03. Recorded outcome: Chose cell-free DNA (low risk) with the nuchal translucency scan (1.7 mm); declined diagnostic testing. **S**
- Blood pressure below 140/90 mmHg with aspirin taken nightly from 13 weeks. Target: 2026-07-12. Recorded outcome: Blood pressure 104/62 to 112/70 mmHg throughout; aspirin taken nightly. **S**
- A written delivery and postpartum hemorrhage plan agreed by 36 weeks, with birth planned in a hospital with a blood bank and operating theatre. Target: 2026-06-02. Recorded outcome: Plan agreed at 34 weeks: induction at 39 weeks at the hospital, oxytocin after birth, quantitative blood loss, and tranexamic acid ready. **S**
- A postpartum contraception choice and a plan for the interval before any future pregnancy, made on her own terms before delivery. Target: 2026-06-02. Recorded outcome: Chose an etonogestrel implant before discharge after the birth; plans at least 18 to 24 months before any future pregnancy. **S**

## What we agreed to do

- First prenatal visit: dating and nuchal translucency scan; blood count, ferritin, blood group and antibody screen, rubella immunity, hepatitis B surface antigen, HIV, syphilis, and hepatitis C tests; urine culture for asymptomatic bacteriuria; hemoglobin electrophoresis for microcytosis; hemoglobin A1c as an early diabetes screen; influenza vaccine; folic acid. Guideline: Pregnancy at Age 35 Years or Older: ACOG Obstetric Care Consensus No. 11 (2022); USPSTF A and B Recommendations (2026); Guidelines for Vaccinating Pregnant Persons (2026) **S**
- Aneuploidy screening offered, with diagnostic testing available: cell-free DNA and the nuchal translucency measurement today, or chorionic villus sampling or amniocentesis; she chose cell-free DNA. Guideline: Pregnancy at Age 35 Years or Older: ACOG Obstetric Care Consensus No. 11 (2022); Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226 (2020) **S**
- Maternal-fetal medicine consultation for a fourteenth pregnancy at 37 with a short interpregnancy interval and anemia: surveillance, anemia treatment, placental assessment, delivery timing and place, and postpartum hemorrhage planning. Guideline: Pregnancy at Age 35 Years or Older: ACOG Obstetric Care Consensus No. 11 (2022); Practice Bulletin No. 183: Postpartum Hemorrhage (2017) **S**
- Iron deficiency anemia: ferrous sulfate 325 mg every other day; repeat blood count and ferritin in four weeks, with intravenous iron in the second trimester if she cannot tolerate oral iron or the hemoglobin does not rise; aim for hemoglobin of 11 g/dL or more before delivery. Guideline: Anemia in Pregnancy: ACOG Practice Bulletin, Number 233 (2021) **S**
- Preeclampsia prevention: aspirin 81 mg at bedtime from 13 weeks until delivery for two moderate risk factors (age 35 or older and a previous adverse pregnancy outcome); blood pressure and urine protein at every visit. Guideline: Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication (2021) **S**
- Detailed anatomy scan at 20 to 22 weeks with placental location; if the placenta is low-lying or covers the cervix, a repeat scan at 32 weeks and assessment for placenta accreta spectrum. Guideline: Pregnancy at Age 35 Years or Older: ACOG Obstetric Care Consensus No. 11 (2022); Obstetric Care Consensus No. 7: Placenta Accreta Spectrum (2018) **S**
- Gestational diabetes: hemoglobin A1c today because she is of South Asian heritage with a BMI of 23 or more; one-hour glucose challenge at 24 to 28 weeks. Guideline: ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus (2018) **S**
- Travel: travel is reasonable until about 36 weeks if the pregnancy stays uncomplicated; on long journeys walk every one to two hours, drink plenty, and wear compression stockings; carry her prenatal record; find maternity care where she stays; stay near the delivery hospital from 36 weeks. Guideline: ACOG Committee Opinion No. 746: Air Travel During Pregnancy (2018) **S**
- Postpartum hemorrhage risk assessment at intake and again in the third trimester and on admission for birth (grand multiparity and anemia raise her risk); delivery planned in a hospital with a blood bank, anesthesia, and an operating theatre. Guideline: Practice Bulletin No. 183: Postpartum Hemorrhage (2017); WHO recommendations for the prevention and treatment of postpartum haemorrhage (2012) **S**
- Mood: EPDS in each trimester, with support for the grief of having lost several children. Guideline: Screening and Diagnosis of Mental Health Conditions During Pregnancy and Postpartum (Clinical Practice Guideline No. 4) (2023) **S**
- Postpartum hemorrhage plan for birth: induction at 39 weeks in hospital; type and screen and blood count on admission; two large-bore intravenous lines; avoid prolonged labor, with timely assessment of progress; oxytocin 10 units after birth as active management of the third stage; quantitative blood loss; tranexamic acid 1 g intravenously within 3 hours of birth if hemorrhage is diagnosed, with a second 1 g dose if bleeding continues after 30 minutes; second-line uterotonics, a uterine balloon, and the massive transfusion protocol ready. Guideline: Pregnancy at Age 35 Years or Older: ACOG Obstetric Care Consensus No. 11 (2022); Practice Bulletin No. 183: Postpartum Hemorrhage (2017); WHO recommendations for the prevention and treatment of postpartum haemorrhage (2012); WHO recommendation on tranexamic acid for the treatment of postpartum haemorrhage (2017); Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial (2017) **S**
- Contraception and interpregnancy interval, on her own terms: options explained (implant, hormonal or copper IUD, progestin-only pill, lactational amenorrhea, and permanent methods); she chose an etonogestrel implant before discharge after the birth and plans to wait at least 18 to 24 months before any future pregnancy. Guideline: Obstetric Care Consensus No. 8: Interpregnancy Care (2019); U.S. Medical Eligibility Criteria for Contraceptive Use, 2024 (2024) **S**

## Follow-up

- 2026-01-06: First prenatal visit at 13 weeks in a fourteenth pregnancy: dating and nuchal translucency scan, prenatal tests, and a high-risk plan **S**
- 2026-02-03: Prenatal visit at 17 weeks, with maternal-fetal medicine consultation **S**
- 2026-03-03: Prenatal visit at 21 weeks with the anatomy scan and placental location **S**
- 2026-04-14: Prenatal visit at 27 weeks: glucose challenge, blood count, and Tdap **S**
- 2026-06-02: Prenatal visit at 34 weeks: growth scan, postpartum hemorrhage risk assessment, delivery plan, and contraception counseling **S**

This teaching document does not replace care from a qualified clinician.
